These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27288434)

  • 21. 5-Hydroxymethylcytosine preferentially targets genes upregulated in isocitrate dehydrogenase 1 mutant high-grade glioma.
    Glowacka WK; Jain H; Okura M; Maimaitiming A; Mamatjan Y; Nejad R; Farooq H; Taylor MD; Aldape K; Kongkham P
    Acta Neuropathol; 2018 Apr; 135(4):617-634. PubMed ID: 29428975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
    Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
    Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-Jun-N-terminal phosphorylation regulates DNMT1 expression and genome wide methylation in gliomas.
    Heiland DH; Ferrarese R; Claus R; Dai F; Masilamani AP; Kling E; Weyerbrock A; Kling T; Nelander S; Carro MS
    Oncotarget; 2017 Jan; 8(4):6940-6954. PubMed ID: 28036297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutant IDH1 regulates the tumor-associated immune system in gliomas.
    Amankulor NM; Kim Y; Arora S; Kargl J; Szulzewsky F; Hanke M; Margineantu DH; Rao A; Bolouri H; Delrow J; Hockenbery D; Houghton AM; Holland EC
    Genes Dev; 2017 Apr; 31(8):774-786. PubMed ID: 28465358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular subclassification of diffuse gliomas: seeing order in the chaos.
    Huse JT; Phillips HS; Brennan CW
    Glia; 2011 Aug; 59(8):1190-9. PubMed ID: 21446051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications.
    Malta TM; de Souza CF; Sabedot TS; Silva TC; Mosella MS; Kalkanis SN; Snyder J; Castro AVB; Noushmehr H
    Neuro Oncol; 2018 Apr; 20(5):608-620. PubMed ID: 29036500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.
    Paz MF; Yaya-Tur R; Rojas-Marcos I; Reynes G; Pollan M; Aguirre-Cruz L; García-Lopez JL; Piquer J; Safont MJ; Balaña C; Sanchez-Cespedes M; García-Villanueva M; Arribas L; Esteller M
    Clin Cancer Res; 2004 Aug; 10(15):4933-8. PubMed ID: 15297393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
    Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P
    Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
    Agnihotri S; Aldape KD; Zadeh G
    Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
    Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glioma biology and molecular markers.
    Cohen AL; Colman H
    Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA demethylation is associated with malignant progression of lower-grade gliomas.
    Nomura M; Saito K; Aihara K; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Tanaka S; Takayanagi S; Otani R; Nejo T; Hana T; Takahashi S; Kitagawa Y; Omata M; Higuchi F; Nakamura T; Muragaki Y; Narita Y; Nagane M; Nishikawa R; Ueki K; Saito N; Aburatani H; Mukasa A
    Sci Rep; 2019 Feb; 9(1):1903. PubMed ID: 30760837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype.
    Whitehall VL; Dumenil TD; McKeone DM; Bond CE; Bettington ML; Buttenshaw RL; Bowdler L; Montgomery GW; Wockner LF; Leggett BA
    Epigenetics; 2014 Nov; 9(11):1454-60. PubMed ID: 25496513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glioma epigenetics: From subclassification to novel treatment options.
    Gusyatiner O; Hegi ME
    Semin Cancer Biol; 2018 Aug; 51():50-58. PubMed ID: 29170066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CIMP-positive glioma is associated with better prognosis: A systematic analysis.
    Xu Y; Xiao H; Hu W; Shen HC; Liu W; Tan S; Ren C; Zhang X; Yang X; Yu G; Yang T; Yu D; Zong L
    Medicine (Baltimore); 2022 Sep; 101(39):e30635. PubMed ID: 36181110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.
    van den Bent MJ; Gravendeel LA; Gorlia T; Kros JM; Lapre L; Wesseling P; Teepen JL; Idbaih A; Sanson M; Smitt PA; French PJ
    Clin Cancer Res; 2011 Nov; 17(22):7148-55. PubMed ID: 21914791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.